Why the study?
Guidelines recommend TAVI only at centers with on-site cardiac surgery, but reduced complications and procedural advances suggest TAVI without on-site surgery could reduce waiting times and improve continuity of care.
Does performing transfemoral TAVI at hospitals without on-site cardiac surgery achieve non-inferior 30-day all-cause mortality compared to historical standards in patients >75 years with severe symptomatic aortic stenosis at high or prohibitive surgical risk?
Does performing transfemoral TAVI at hospitals without on-site cardiac surgery achieve non-inferior 30-day all-cause mortality compared to historical standards in patients >75 years with severe symptomatic aortic stenosis at high or prohibitive surgical risk?
This prospective study protocol outlines the design to evaluate the feasibility and safety of performing transfemoral TAVI in hospitals without on-site cardiac surgery for elderly, high- or prohibitive-risk aortic stenosis patients to potentially reduce waiting list mortality.
Answers are grounded in this paper and cite their sources.
Should not yet change the on-site CS mandate; leaves open whether selected TAVI without surgical backup is safe.
Transcatheter aortic valve implantation (TAVI) has become the standard of care for elderly patients with aortic stenosis. International guidelines recommend that TAVI should be performed only in centers with on-site cardiac surgery (CS). However, rapidly evolving TAVI technology and increasing operator expertise have significantly reduced peri-procedural complications, including those requiring rescue surgery, which occur in less than 0.5% of cases. Furthermore, only a minority of major complications are treated with CS, and the outcomes remain unfavorable. TAVI in centers without CS could represent a solution to reduce waiting times and ensure continuity of care for fragile patients. "TAVI at Home" is a single-arm prospective interventional study. According to sample size calculations based on literature data, the study aims to enroll a total of 200 patients, beginning with a run-in phase of 20 patients to establish safety. The primary endpoint is 30-day all-cause mortality. Secondary endpoints include technical success and the evaluation of single complications 30 days after the procedure. Hospitals without CS that are eligible to perform TAVI must have a high volume of coronary percutaneous interventions, operators with established TAVI experience, collaboration with vascular surgeons, and regular Heart Team meetings to ensure rigorous patient selection.
No takes yet. Share an insight, caveat, or question.
Compagnone et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: